Forecast

There is no analyst data available for this company.

News Go to news feed

Q-linea Registered: loss per share significantly reduced, revenue rises 508.77%

Q-linea Registered published results for the quarter ended 30.09.2025. Loss per share fell to 6.55 SEK from -50,940 SEK in the same quarter a year earlier. Revenue increased to 3.5 million SEK, up 508.77% from 0.6 million SEK in the prior year. » More on finanzen.net
Q-linea reports 370% rise in recurring revenue and plans cost cuts

Q-linea recorded a 370% year‑on‑year increase in recurring revenue in Q3 2025. The company reduced headcount from 150 to 83 employees and aims to lower monthly operating costs to SEK 11.3–11.8 million by 2026. Q-linea holds SEK 42.6 million in cash, plans a rights issue of SEK 322 million (85.6% secured) and targets installation of 30 ASTar systems by year‑end; the V2 menu is planned for FDA submission. The share price traded slightly weaker after the earnings call (-0.02%). » More on de.investing.com

Financials

In the last quarter, Q-LINEA AB had revenue of €135.36K and net profit of -€2.7M

(EUR)	Jun 2026	YoY
Revenue	135.36K	39.26%
Gross profit	-3.11M	2,012.46%
Net profit	-2.7M	37.48%
EBITDA	-2.78M	28.82%

Fundamentals

Metric	Value
Market capitalization	€11.05M
Number of shares	6.66M
52-week high/low	€4.72 - €1.31
Dividends	No
Beta	0.59
P/E ratio	-1.40
PEG ratio	0.02
P/B ratio	1.27
P/S ratio	12.46

Company profile

Q-linea AB (publ) beschäftigt sich mit der Entwicklung von Instrumenten und Verbrauchsmaterialien für die Infektionsdiagnostik in Schweden. Das Unternehmen bietet innovative Systeme für die In-vitro-Diagnostik von Infektionskrankheiten an. Der führende Produktkandidat des Unternehmens ist ASTar, ein System zum Testen der Antibiotikaempfindlichkeit bei positiven Blutkulturen. Das Unternehmen entwickelt und liefert Lösungen für Gesundheitsdienstleister. Q-linea AB (publ) wurde im Jahr 2008 gegründet und hat seinen Hauptsitz in Uppsala, Schweden.